{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-005009","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.900033+00:00","generated_at":"2026-05-28T03:13:22.477861+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Annexon provides 2025 outlook; targets BLA submission for ANX005 in GBS in 1H 2025","bullets":["ANX005 for GBS: Phase 3 showed rapid muscle strength improvement vs placebo; BLA submission targeted for 1H 2025.","ANX007 for GA: Phase 3 ARCHER II enrollment on track for completion in 2H 2025; data expected 2H 2026.","ANX1502 oral C1s inhibitor: clinical proof-of-concept data in CAD expected in 1Q 2025.","Cash runway sufficient into 2H 2026 to achieve key milestones.","Positive Phase 2 ARCHER data for ANX007 showed significant vision preservation on BCVA and LLVA endpoints."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-005009","json":"https://secwatch.observer/filing/0001193125-25-005009.json","markdown":"https://secwatch.observer/filing/0001193125-25-005009.md","text":"https://secwatch.observer/filing/0001193125-25-005009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312525005009/0001193125-25-005009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312525005009/d38866d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:13:22.477861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}